- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04370522
Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer (NIKOLE)
The NIKOLE Study: Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer
Study Overview
Status
Conditions
Detailed Description
After enrolment, patients will be assigned to one of the following cohorts according to their level of hormone-resistance:
- Cohort A (hormone-sensitive disease).
- Cohort B (hormone-resistant disease).
In both cohorts it will be collected residual pre-treatment tumor samples from metastatic lesions, preferably obtained after last treatment just prior to study entry, and/or primary breast tumor; as well as serial blood samples at baseline, after 6 weeks, at the same time of radiological re-evaluation (3 months after ET initiation) and at progressive disease (PD) which will be used for serial analytic determinations of the expression profiles of Natural Killer (NK) cells, other lymphoid innate cells, NKG2D ligands, cytokines and other possible biomarkers; in addition to obtain local data of hemogram and estradiol, Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) levels.
Patients who have participated in the study during their first line of ET are eligible to participate after progression, when they initiate the second line of ET (in this case, inclusion/exclusion criteria should be checked newly and Informed Consent Form (ICF) signed again).
From the control population it will be collected blood and local data (e.g. hemogram, estradiol, FSH and LH levels), in a single time-point after ICF signature.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Murcia, Spain, 30008
- Hospital General Universitario Morales Meseguer
-
Valencia, Spain, 46010
- Hospital Clínico Universitario de Valencia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
INCLUSION AND EXCLUSION CRITERIA OF PATIENTS
Inclusion Criteria:
- Female ≥ 18 years of age on day of signing informed consent.
- Patient with histological confirmation of BC with evidence of metastatic or advanced disease not amenable to resection or radiation therapy with curative intent.
- Documented Hormonal Receptor (HR) positive status based on local testing (preferably assessed on the most recent tumour biopsy available). HR+ is defined as ≥ 1% positive cells by immuno-histochemistry (IHC) for ER and/or Progesterone Receptor (PgR).
- Documented HER2 negative status based on local testing (preferably assessed on the most recent tumour biopsy available). HER2- is defined as IHC score 0/1+ or negative by in situ hybridization according to local criteria.
- Patients who are going to receive ET in first or second line for advanced disease (in monotherapy or in combination). It is allowed the inclusion of patients that have received or are going to initiate tamoxifen, Luteinizing Hormone Releasing Hormone (LHRH) analogues, aromatase inhibitors or fulvestrant. It is also possible to recruit patients that have received or are going to initiate cyclin or mTOR inhibitors in combination with ET. (NOTE: it is not allowed the inclusion of patients after first line of chemotherapy that are in response and initiate maintenance ET).
- Patients who have participated in the study during their first line of ET are eligible to participate again when they receive the second line of ET (in this case eligibility criteria should be checked newly and ICF signed again).
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
- Patient must have a life expectancy ≥ 16 weeks.
- The patient has signed and dated the ICF for study participation.
- Willingness and ability to comply with the protocol for the duration of the study including biological sample collection.
Exclusion Criteria:
- Have received more than 1 prior therapy line for advanced BC disease.
- Have received chemotherapy with response and initiate ET as maintenance treatment.
- Locally advanced breast cancer.
- Previous or concomitant treatment with immunotherapeutic agents.
- Major surgical procedure unrelated to breast cancer or significant traumatic injury within 28 days prior to study entry.
- History of concurrent or previously treated non-breast malignancies except for appropriately treated 1) non-melanoma skin cancer and/or 2) in situ carcinomas, including cervix and colon.
- Has a diagnosis of immunodeficiency, autoimmune disease or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of ET.
- Has an active infection requiring systemic therapy. Patients with solved infection that has finished antibiotic treatment within 7 days prior to study entry could be included.
- Has a known history of active Tuberculosis Bacillus (TB) or Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or a known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (HCV) (e.g. HCV RNA [qualitative] is detected).
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- There is evidence that the patient is pregnant or breastfeeding, or patient is expecting to conceive within the projected duration of the study.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the investigator.
In the case of values of Neutrophil Count (NC) < 1.5 x 109/L prior to study entry or in case of patients who have received or are going to receive an investigational product, the information about NC or the investigational product should be checked with chief investigator in order to check any possible interference with the study results.
INCLUSION CRITERIA OF CONTROL PARTICIPANTS
- Female ≥ 18 years of age on day of signing informed consent.
- The participant has signed and dated the ICF for study participation.
- Absence of evidences of current tumor malignancies or active infectious disease.
- Absence of history or current evidences of immunological and rheumatologic diseases or any condition, therapy, or laboratory abnormality that might confound the results of the study, in the opinion of the investigator.
- Willingness and ability to comply with blood and study data collection.
- To have data to be able to be classified as pre- o postmenopausal.
Postmenopausal women are defined as women fulfilling any one of the following criteria (based on the National Comprehensive Cancer Network (NCCN) definition of menopause [NCCN 2008]):
- Prior bilateral oophorectomy.
- Age > 60 years.
- Age ≤ 60 years and with amenorrhea for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and estradiol in the postmenopausal range.
Women who didn't comply with any of the prior criteria will be considered premenopausal women for the purposes of the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Cohort A: hormone-sensitive disease
Patients who initiate ET in first line of advanced disease, they could be patients de novo with no previous ET or patients who received adjuvant ET and experience disease recurrence more than one year after its completion. Patients will be divided in two subgroups according to having or not received previous ET. |
Cohort B: hormone-resistant disease
Patients in progression who are starting a first or second line of ET for advanced Breast Cancer (BC) and showing one of following the hormone-resistance criteria to any ET: For first line:
For second line:
Patients will be divided in two subgroups according to having primary or secondary hormone-resistance. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of innate immune cells
Time Frame: Up to disease progression, an average of 25 months
|
Amount of the different populations of innate immune cells (e.g. NK cells, ILC1, ILC2 and ILC3) detected in tumor tissue and/or serial peripheral blood samples. Blood samples will be collected from the patients at the following time-points: at baseline, after 6 weeks, at tumor re-evaluation of treatment and after end of therapy (before the beginning of the next treatment). Blood samples will be collected from the control participants in a single time-point after signature of the corresponding Inform Consent Form. It is required the shipment of residual pre-treatment tumor samples (leftover from medical routine assistance) from primary and/or the recurrence/metastatic sites, preferably obtained after the last treatment prior to study entry. |
Up to disease progression, an average of 25 months
|
Activation level of innate immune cells
Time Frame: Up to disease progression, an average of 25 months
|
Activation level of the different populations of innate immune cells (e.g. NK cells, ILC1, ILC2 and ILC3) detected in tumor tissue and/or serial peripheral blood samples. Blood samples will be collected from the patients at the following time-points: at baseline, after 6 weeks, at tumor re-evaluation of treatment and after end of therapy (before the beginning of the next treatment). Blood samples will be collected from the control participants in a single time-point after signature of the corresponding Inform Consent Form. It is required the shipment of residual pre-treatment tumor samples (leftover from medical routine assistance) from primary and/or the recurrence/metastatic sites, preferably obtained after the last treatment prior to study entry. |
Up to disease progression, an average of 25 months
|
Analyses of the expression level of cytokines and/or rNKG2D ligands
Time Frame: Up to disease progression, an average of 25 months
|
Analyses of the expression level of cytokines and/or rNKG2D ligands in tumor tissue and/or serial peripheral blood samples. Blood samples will be collected from the patients at the following time-points: at baseline, after 6 weeks, at tumor re-evaluation of treatment and after end of therapy (before the beginning of the next treatment). Blood samples will be collected from the control participants in a single time-point after signature of the corresponding Inform Consent Form. It is required the shipment of residual pre-treatment tumor samples (leftover from medical routine assistance) from primary and/or the recurrence/metastatic sites, preferably obtained after the last treatment prior to study entry. |
Up to disease progression, an average of 25 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS) in relation with values of innate immune cells, cytokines and ligands of rNKG2D
Time Frame: Up to disease progression, an average of 25 months
|
Progression Free Survival (PFS) defined as the time from the start of therapy to the first documented progressive disease, or death from any cause, whichever occurs first.
Progressive disease will be based on the investigator's assessment according to the standard institutional guidelines, and following as much as possible RECIST version 1.1.
Tumor assessment during treatment will be performed according the clinical standard of care and following as much as possible RECIST version 1.1.
every 3 months (+/- 1 month).
|
Up to disease progression, an average of 25 months
|
Objective Response Rate (ORR) in relation with values of innate immune cells, cytokines and ligands of rNKG2D
Time Frame: Up to disease progression, an average of 25 months
|
OR rate (ORR) is defined as the Complete Response (CR) + Partial Response (PR) out of the patients who had measurable disease at baseline, according to the standard institutional guidelines and following as much as possible the RECIST version 1.1.
Tumor assessment during treatment will be performed according the clinical standard of care and following as much as possible RECIST version 1.1.
every 3 months (+/- 1 month).
|
Up to disease progression, an average of 25 months
|
Clinical Benefit (CB) in relation with values of innate immune cells, cytokines and ligands of rNKG2D
Time Frame: Up to disease progression, an average of 25 months
|
Clinical Benefit (CB): is defined as complete response (CR), partial response (PR), or stable disease (SD) lasting more than 24 weeks; based on the investigator's assessment according to the standard institutional guidelines, and following as much as possible according to the RECIST version 1.1.
The definition of Response/non-Response and Stable Disease will be based on the RECIST version 1.1.
Tumor assessment during treatment will be performed according the clinical standard of care and following as much as possible RECIST version 1.1.
every 3 months (+/- 1 month).
|
Up to disease progression, an average of 25 months
|
Collaborators and Investigators
Investigators
- Study Director: Study Director, Hospital General Universitario Morales Meseguer
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GEICAM/2018-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance